6 results on '"Nambiar, Anoop M."'
Search Results
2. Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis.
- Author
-
Nambiar, Anoop M., Anzueto, Antonio R., and Peters, Jay I.
- Subjects
- *
MYCOPHENOLIC acid , *COLLAGEN diseases , *PULMONARY fibrosis , *LUNG diseases , *WOUNDS & injuries - Abstract
Background: Currently available antifibrotic treatments may slow down disease progression in idiopathic pulmonary fibrosis (IPF), but are associated with potentially significant side effects and are costly. Mycophenolate mofetil (MMF) is well known for its potent immunosuppressive properties and possesses important antiproliferative and antifibrotic effects. The safety and effectiveness of MMF in IPF is unknown. Methods: We performed a retrospective multicohort analysis of IPF patients treated with MMF compared to those treated with either ineffective/harmful treatments or no treatment. Longitudinal change in forced vital capacity (FVC) between the groups was analyzed using a mixed model with random intercept and slope allowing for repeated measures within subjects. Categorical change in FVC, median overall survival, and adverse events were also assessed. Results: Forty-one IPF patients were included: 11 treated with MMF, 20 treated with ineffective/harmful agents (such as prednisone, azathioprine, and/or NAC), and 10 did not receive any specific treatment for their IPF. After one year, there was a trend towards reduced FVC decline in the MMF-treated group (-76.3 mL, -2.4% of predicted) compared to the non-MMF-treated (-165 mL, -8.9% of predicted) and the no-treatment (-239 mL, -11.5% of predicted) groups, respectively. By categorical change, there was a trend towards greater FVC stability in the MMF-treated group (87.5%) compared to the non-MMF-treated (57%) and the no-treatment groups (50%), respectively. MMF-treated IPF patients had a trend towards improved median overall survival (40.3 months) compared to the non-MMF-treated (25.5 months) and the no-treatment (29.3 months) groups, respectively. Treatment-related adverse events were not different between groups; however, very few adverse events were reported overall. Conclusions: MMF treatment was associated with potentially clinically important trends toward reduced annual FVC decline (similar to approved antifibrotics), greater FVC stability and improved overall survival in IPF patients. MMF was generally safe, well tolerated, and relatively inexpensive. Future prospective studies of MMF in combination with antifibrotic therapy in IPF are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
3. Combination pirfenidone and inhaled N-acetylcysteine therapy for IPF: Does it take these two to tango?
- Author
-
Velez, Maria I. and Nambiar, Anoop M.
- Subjects
- *
COMBINATION drug therapy , *ACETYLCYSTEINE , *IDIOPATHIC pulmonary fibrosis , *THERAPEUTICS - Abstract
See article, page 445 [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
4. Procalcitonin in acute exacerbations of interstitial pneumonia: Another tool in the toolbox?
- Author
-
Nambiar, Anoop M.
- Subjects
- *
ADULT respiratory distress syndrome , *DISEASE exacerbation - Abstract
See article, page 439 [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
5. Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial.
- Author
-
Martinez, Fernando J., Yow, Eric, Flaherty, Kevin R., Snyder, Laurie D., Durheim, Michael T., Wisniewski, Stephen R., Sciurba, Frank C., Raghu, Ganesh, Brooks, Maria M., Kim, Dong-Yun, Dilling, Daniel F., Criner, Gerard J., Kim, Hyun, Belloli, Elizabeth A., Nambiar, Anoop M., Scholand, Mary Beth, Anstrom, Kevin J., Noth, Imre, and CleanUP-IPF Investigators of the Pulmonary Trials Cooperative
- Subjects
- *
IDIOPATHIC pulmonary fibrosis , *CO-trimoxazole , *DOXYCYCLINE , *ANTI-infective agents , *CLINICAL trials , *LUNG microbiology , *ANTIBIOTICS , *RESEARCH , *RESEARCH methodology , *RESPIRATORY infections , *MEDICAL cooperation , *EVALUATION research , *TREATMENT effectiveness , *COMPARATIVE studies , *RANDOMIZED controlled trials , *PULMONARY function tests , *HOSPITAL care , *RESEARCH funding - Abstract
Importance: Alteration in lung microbes is associated with disease progression in idiopathic pulmonary fibrosis.Objective: To assess the effect of antimicrobial therapy on clinical outcomes.Design, Setting, and Participants: Pragmatic, randomized, unblinded clinical trial conducted across 35 US sites. A total of 513 patients older than 40 years were randomized from August 2017 to June 2019 (final follow-up was January 2020).Interventions: Patients were randomized in a 1:1 allocation ratio to receive antimicrobials (n = 254) or usual care alone (n = 259). Antimicrobials included co-trimoxazole (trimethoprim 160 mg/sulfamethoxazole 800 mg twice daily plus folic acid 5 mg daily, n = 128) or doxycycline (100 mg once daily if body weight <50 kg or 100 mg twice daily if ≥50 kg, n = 126). No placebo was administered in the usual care alone group.Main Outcomes and Measures: The primary end point was time to first nonelective respiratory hospitalization or all-cause mortality.Results: Among the 513 patients who were randomized (mean age, 71 years; 23.6% women), all (100%) were included in the analysis. The study was terminated for futility on December 18, 2019. After a mean follow-up time of 13.1 months (median, 12.7 months), a total of 108 primary end point events occurred: 52 events (20.4 events per 100 patient-years [95% CI, 14.8-25.9]) in the usual care plus antimicrobial therapy group and 56 events (18.4 events per 100 patient-years [95% CI, 13.2-23.6]) in the usual care group, with no significant difference between groups (adjusted HR, 1.04 [95% CI, 0.71-1.53; P = .83]. There was no statistically significant interaction between the effect of the prespecified antimicrobial agent (co-trimoxazole vs doxycycline) on the primary end point (adjusted HR, 1.15 [95% CI 0.68-1.95] in the co-trimoxazole group vs 0.82 [95% CI, 0.46-1.47] in the doxycycline group; P = .66). Serious adverse events occurring at 5% or greater among those treated with usual care plus antimicrobials vs usual care alone included respiratory events (16.5% vs 10.0%) and infections (2.8% vs 6.6%); adverse events of special interest included diarrhea (10.2% vs 3.1%) and rash (6.7% vs 0%).Conclusions and Relevance: Among adults with idiopathic pulmonary fibrosis, the addition of co-trimoxazole or doxycycline to usual care, compared with usual care alone, did not significantly improve time to nonelective respiratory hospitalization or death. These findings do not support treatment with these antibiotics for the underlying disease.Trial Registration: ClinicalTrials.gov Identifier: NCT02759120. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
6. Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases.
- Author
-
Amati, Francesco, Stainer, Anna, Mantero, Marco, Gramegna, Andrea, Simonetta, Edoardo, Suigo, Giulia, Voza, Antonio, Nambiar, Anoop M., Cariboni, Umberto, Oldham, Justin, Molyneaux, Philip L., Spagnolo, Paolo, Blasi, Francesco, and Aliberti, Stefano
- Subjects
- *
PULMONARY fibrosis , *INTERSTITIAL lung diseases , *IDIOPATHIC pulmonary fibrosis , *LUNGS - Abstract
Interstitial lung diseases represent a heterogeneous and wide group of diseases in which factors leading to disease initiation and progression are not fully understood. Recent evidence suggests that the lung microbiome might influence the pathogenesis and progression of interstitial lung diseases. In recent years, the utilization of culture-independent methodologies has allowed the identification of complex and dynamic communities of microbes, in patients with interstitial lung diseases. However, the potential mechanisms by which these changes may drive disease pathogenesis and progression are largely unknown. The aim of this review is to discuss the role of the altered lung microbiome in several interstitial lung diseases. Untangling the host–microbiome interaction in the lung and airway of interstitial lung disease patients is a research priority. Thus, lung dysbiosis is a potentially treatable trait across several interstitial lung diseases, and its proper characterization and treatment might be crucial to change the natural history of these diseases and improve outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.